Neos Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Neos Therapeutics (US): 2 reconciled FDA prescription therapies, $24.1M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2032-01-01
2024 CMS Total Public Spend$24.1M
2024 Medicare Part D Spend$1.3M
2024 Medicaid Spend$22.8M
California HCAI SB 17 Filings9 WAC filings (max 20.9% 2-yr change)